We bring you the latest news from the healthcare about the health care in the United Kingdom.

maandag 29 oktober 2018

The Lancet: [Comment] 9 weeks that matter for patients with gastric cancer

[Comment] 9 weeks that matter for patients with gastric cancer
Unresectable advanced or metastatic gastric cancer remains a difficult-to-manage disease, with poor median overall survival associated with first-line and second-line palliative systemic treatment. Therefore, there is an urgent need to further improve survival and to provide additional therapeutic options to patients who do not respond to or do not tolerate first-line and second-line chemotherapy regimens.
Read more

[Articles] Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial
Trifluridine/tipiracil significantly improved overall survival compared with placebo and was well tolerated in this heavily pretreated population of patients with advanced gastric cancer. Trifluridine/tipiracil could be a new treatment option in this population who represent a high unmet medical need.
Read more

[Articles] Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
The results of this analysis at 4 years of follow-up show that a durable, sustained survival benefit can be achieved with first-line nivolumab plus ipilimumab or nivolumab alone in patients with advanced melanoma.
Read more

[Comment] Long-term survival with anti-PD-1-based immunotherapy, but what is the best approach?
Checkpoint inhibitor immunotherapy has transformed the treatment of melanoma in the past 7 years, and can even lead to durable long-term survival outcomes in some patients with metastatic disease.1 However, we still have much to learn about how best to use these drugs and how to mitigate their side-effects. The optimal combination regimens, treatment duration, patient selection, and the point in the disease trajectory at which immunotherapy can be deployed to best effect remain open questions.
Read more

[News] Neoadjuvant pembrolizumab in bladder cancer
Pembrolizumab might be an effective neoadjuvant therapy for the treatment of muscle-invasive bladder cancer—especially in patients with programmed death-ligand 1 (PD-L1)-positive or high mutation burden tumours—according to a recent study.
Read more